Overview
GLP-1 NAION lawsuits — MDL 3163, In Re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Products Liability Litigation, consolidated in the Eastern District of Pennsylvania before Judge Karen Spencer Marston (per JPML). Claimants allege that GLP-1 drugs — including Ozempic, Wegovy, and Saxenda (Novo Nordisk) and Trulicity (Eli Lilly) — caused NAION ("eye stroke"), sudden vision loss or blindness, on failure-to-warn, design-defect, and warranty theories. Per the JPML, MDL 3094 (GI injuries) is a related, separate MDL in the same district. Causation is contested. We track public records — we do not promise outcomes.
Status of the science / claims: Association under study: FDA has reviewed adverse-event reports linking GLP-1 receptor agonists to NAION ("eye stroke"); causation is not established and remains contested (per FDA and published literature). The JPML found common questions concerning development, manufacture, testing, regulatory history, promotion, and labeling of GLP-1 RAs and their capacity to cause NAION (per E.D. Pa. court page).
Key people
Companies involved
Settlement amounts
No global settlement as of this update. Individual case values are not public; per claimant reports, early matters remain in discovery. Any figures published by firms are illustrative, not promised.
Case count
| Month | Filed cases | Δ |
|---|---|---|
| Jul 1, 2026 | 120 | +30 |
| Jan 1, 2026 | 90 | +30 |
| Oct 1, 2025 | 60 | +35 |
| Jul 1, 2025 | 25 | — |
Key dates
- August 1, 2026Monthly status conferences; 2026 Scheduling Order (per E.D. Pa. court page); intake active
- December 15, 2025JPML transfer/centralization: MDL 3163 in E.D. Pa., Judge Karen Spencer Marston (per JPML)
- July 1, 2025First wave of individual lawsuits filed (per plaintiff firm announcements)
- June 1, 2024FDA begins reviewing FAERS reports of vision loss in GLP-1 users (per FDA communications)
Updates
- Updated Sep 1, 2026MDL 3163 confirmed under Judge Karen Spencer Marston (E.D. Pa.); JPML transfer Dec 15, 2025 (per JPML).
- Updated Aug 1, 2026Lanier Law published August 2026 update; Nigh & Goldenberg advertising MDL leadership.
Notable filings
- — First wave complaint — semaglutide NAION (per firm announcement) [source] — Early individual complaint alleging failure-to-warn for semaglutide-related NAION (per plaintiff firm pages; docket to be confirmed by signal-агент).
FAQ
What is the GLP-1 NAION lawsuit about?
Claimants allege that GLP-1 drugs caused NAION (non-arteritic anterior ischemic optic neuropathy, sometimes called an “eye stroke”), sudden vision loss, or blindness, on failure-to-warn, design-defect, and warranty theories (per the MDL caption and complaints). The MDL covers GLP-1 receptor agonist drugs (per the MDL caption).
Which drugs are covered?
The consolidated action covers GLP-1 receptor agonist drugs. Public dockets and complaints reference semaglutide products (Ozempic, Wegovy) and tirzepatide products (Mounjaro, Zepbound) (per public dockets).
Where is the MDL and who is the judge?
MDL 3163, In Re: GLP-1 RAs NAION Products Liability Litigation, is consolidated in the Eastern District of Pennsylvania before Judge William J. Marston Jr. (per the E.D. Pa. court page). A related MDL 3094 (GI injuries) also exists (per the E.D. Pa. page).
How many cases are in the MDL?
We track about 120 consolidated cases as of August 2026 (per our docket-based count). The number changes as new filings are centralized.
How much will victims receive?
No global settlement is on the public record as of this update. Individual case values are not public; per claimant reports, early matters remain in discovery. Any figures published by firms are illustrative, not promised. No payout amount is available or can be promised.
What is the current status?
The MDL is consolidated and in early stages (per public dockets, August 2026). Scheduling, bellwether selection, and Daubert challenges are typical next steps in this type of MDL (per JPML and court records).
Is there a statute of limitations?
Statutes of limitations vary by state and by injury theory, and the MDL process can extend or toll deadlines. This is not legal advice — consult a licensed attorney about your specific deadline.
Think this matters to you?
This page is neutral reference material — not legal advice. If you were affected, the next step is a free case review with a licensed attorney working this matter.
Start free case review →